ClinicalTrials.gg
CompletedNCT05104931Updated Nov 3, 2021

PK Evaluation of a Nanoformed Oral IR Piroxicam Tablet in Healthy Subjects

A Phase 1 interventional study of Nanoformed Piroxicam IR Tablet and Felden (piroxicam) Tablets in Pain, sponsored by Nanoform Finland Plc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-03.

Sponsored by Nanoform Finland Plc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Dec 2020, registered Mar 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 258 studies in Pain with a site in United Kingdom — 18 open to participants now, 19 under way, 1 of them phase 3. Pain · United Kingdom.

Enrollment
198th of 214
12 · median 78
Started
2020
with 4 others
Phase 1
29 of 258
none open now
Registered
204th of 258
by date

Among the 258 studies in Pain with a site in United Kingdom, this one is the 198th largest by enrollment of the 214 interventional ones that give a count, is one of 5 that started in 2020, is one of 29 in phase 1, and was the 204th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

18 of the 258 studies in Pain with a site in United Kingdom are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 258 studies in Pain with a site in United Kingdom, or all of them as a file.
02

Study summary

Piroxicam is a nonsteroidal anti-inflammatory medication and currently used to treat pain and inflammation caused by osteoarthritis or rheumatoid arthritis. The aim of this study is to study the pharmacokinetic behaviour of the new nanoformed 20mg tablet formulation of piroxicam in comparison with a reference 20mg piroxicam tablet formulation. The target of nanoforming is to improve the pharmacokinetic properties of drugs with low solubility, potentially leading to the use of lower doses with concomitant improvements in safety and tolerability. Piroxicam is an appropriate candidate to demonstrate the benefits of nanoforming due to its physiochemical properties. The efficacy of the Nanoformed Piroxicam is evaluated in comparison to the reference product Felden® Tabs 20 mg. The study also is conducted with a second reference product, Brexidol® 20 mg, or a nanoformed piroxicam tablet of a different strength, or study the effect of food intake on the absorption of the nanofomed piroxicam tablet. The study is conducted with healthy volunteers.

Read the detailed description

This is a single-centre, open-label, partly-randomised, part-cross-over up to three-period, comparative bioavailability study in healthy male and female subjects, designed to investigate the pharmacokinetic (PK) properties and safety of Nanoformed Piroxicam Immediate Release (IR) Tablet, 5 - 20 mg and Felden® (piroxicam) Tablets 20 mg (reference) with an optional Brexidol® (piroxicam) Tablets 20 mg (alternative reference; optional in Period 3. Subjects will receive single oral doses of the investigational medicinal product across up to 3 treatment periods in either the fasted or fed state (optional in Period 3 only). Subjects will be randomised to 1 of 2 treatment sequences across Periods 1 and 2 which will be dosed in the fasted state. Following completion of Period 2, there will be an interim analysis of the PK and safety data generated from both previous periods to decide whether to proceed to an optional Period 3 and, if progression is made, to dose the Nanoformed Piroxicam IR Tablet, 5 - 20 mg in the fed state, an alternative dose level of Nanoformed Piroxicam IR Tablet, 5 - 20 mg in the fasted state or an alternative reference product in the fasted state in Period 3 (optional). The maximum dose of piroxicam that will be administered in any period of the study is 20 mg. For Period 3, if the Nanoformed Piroxicam IR Tablet, 5 - 20 mg formulation is selected, the dose will be selected from a bracketing dose range of 5 to 20 mg. Each period will follow the same study design. There will be a minimum washout of 12 days between each product administration. It is expected that the study will be executed in a single group, requiring a total of 3 study periods.

The study is exploratory and no formal sample size calculation has been made. Based on experience from previous studies of a similar design, a total of 12 subjects are to be enrolled and a minimum of 8 evaluable subjects are considered sufficient.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females
  • Aged 18 to 55 years inclusive at the time of signing
  • (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
  • Must be willing and able to communicate and participate in the whole study
  • Must provide written informed consent
  • Must agree to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1
  • Subjects who are, or are immediate family members of, a study site or sponsor employee
  • Evidence of current SARS-CoV-2 infection
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on type)
  • A confirmed positive alcohol breath test at screening or admission
  • Current smokers and those who have smoked within the last 12 months. A positive urine cotinine test at screening or admission
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Females who are pregnant or lactating (all female subjects must have a negative urine pregnancy test)
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
  • abnormal clinical chemistry, haematology or urinalysis as judged by the investigator
  • Confirmed positive drugs of abuse test result
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) antibody results
  • History of clinically significant cardiovascular (including ischaemic heart disease, peripheral arterial disease, heart failure), renal, hepatic, dermatological, chronic respiratory (including asthma) or neurological or psychiatric disorder, as judged by the investigator
  • History of gastro-intestinal ulceration, bleeding or perforation
  • History of gastrointestinal disorders that predispose to bleeding disorders such as ulcerative colitis, Crohn's disease, gastrointestinal cancers or diverticulitis
  • Subjects with active peptic ulcer, inflammatory gastrointestinal disorder or gastrointestinal bleeding
  • Subjects with a history of cholecystectomy or gall stones
  • History of adverse reactions or allergy associated with any drug
  • Serious adverse reaction or serious to any drug or the formulation
  • History of previous serious allergic drug reaction of any type, especially cutaneous reactions such as erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis
  • Previous skin reaction (regardless of severity) to piroxicam, other NSAIDs and other medications
  • Subjects in whom aspirin and other NSAIDs induce the symptoms of asthma, nasal polyps, angioedema or urticaria
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day or hormonal replacement therapy [HRT]/hormonal ) in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as determined by the investigator
  • Concomitant use of other NSAIDs, including cyclooxygenase-2 inhibitors, selective NSAIDs and acetylsalicylic acid at analgesic doses
  • Failure to satisfy the investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Nanoformed Piroxicam IR Tablet

    orally delivered nanoformed piroxicam immediate release tablets (20mg)

    Drug: Nanoformed Piroxicam IR Tablet

  • Active comparator
    Felden (piroxicam) Tablets

    orally delivered Felden (piroxicam) tablets (20mg)

    Drug: Felden (piroxicam) Tablets

  • Active comparator
    Brexidol (piroxicam) Tablets

    orally delivered Brexidol (piroxicam) tablets (20mg)

    Drug: Nanoformed Piroxicam IR Tablet · Drug: Brexidol (piroxicam) Tablets

Interventions

  • DrugNanoformed Piroxicam IR Tablet

    Orally delivered Nanoformed Piroxicam

    Also known as: Orally delivered Nanoformed Piroxicam IR tablet

  • orally delivered Felden (reference) tablets

    Also known as: orally delivered Felden (piroxicam) tablets

  • orally delivered Brexidol (reference) tablets

    Also known as: orally delivered Brexidol (piroxicam) tablets

06

What researchers measure

Primary outcomes

  1. To determine the Maximum Plasma Concentration (Cmax) of piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state.

    To determine the pharmacokinetics and relative bioavailability of piroxicam over a 72h period following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state by determining the Maximum Plasma Concentration (Cmax).

    Time frame: 72 hours

  2. To determine the Area Under the drug Concentration of piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state.

    To determine the pharmacokinetics and relative bioavailability of piroxicam over a 72h period following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state by determining the Area Under the drug Concentration time curve over 1 hour (AUC(0 1h)), AUC from time 0 to the time of last measurable concentration (AUC(0 last)) and AUC from time 0 extrapolated to infinity (AUC(0-inf)).

    Time frame: 72 hours

  3. To determine the time to Cmax (Tmax) of piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state.

    To determine the pharmacokinetics and relative bioavailability of piroxicam over a 72h period following administration of single oral doses of Nanoformed Piroxicam IR Tablet 5 - 20 mg and Felden (piroxicam) Tablets 20mg (reference) in healthy subjects in the fasted state by determining the time to Cmax (Tmax).

    Time frame: 72 hours

Secondary outcomes

  1. Number of participants that report adverse events (AEs) coded using MedDRA v23.1, pre-dose and 48-72h post-dose, for determining safety and tolerability.

    To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting adverse events (AEs)

    Time frame: 72 hours

  2. To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting supine electrocardiograms

    To assess and report 12 lead supine electrocardiogram-measured P-wave pre-dose and 48-72h post-dose, for determining safety and tolerability.

    Time frame: 72 hours

  3. To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting supine electrocardiograms

    To assess and report 12 lead supine electrocardiogram-measured QT Interval pre-dose and 48-72h post-dose, for determining safety and tolerability.

    Time frame: 72 hours

  4. To assess additional safety and tolerability information for piroxicam following administration of single oral doses of Nanoformed Piroxicam IR Tablet, 5 - 20mg in healthy subjects by assessing and reporting supine electrocardiograms

    To assess and report 12 lead supine electrocardiogram-measured QRS Complex pre-dose and 48-72h post-dose, for determining safety and tolerability.

    Time frame: 72 hours

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Feb 2021, 1 month.

Of 104 industry-sponsored phase 1 interventional studies under Pain, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 9. This study's 1 month is below that.

Counting every sponsor, half of 220 studies reached it within 9 months; a quarter within 3 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2021
First posted
Nov 3, 2021
StartActual
Dec 2, 2020
Primary completionActual
Feb 1, 2021
CompletionActual
Feb 1, 2021
Last update
Nov 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05104931
Lead sponsor
Nanoform Finland Plc
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Dec 2, 2020
Primary completion
Feb 1, 2021
Completion
Feb 1, 2021
Last update
Nov 3, 2021

Study contacts

Philip Evans, MBChB
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Piroxicam

Start the discussion